Pentabromophenol

Research use only, not for human use.

Pentabromophenol suppressed TGF-β response by accelerating the turnover rate of TGF-β receptors.

Pentabromophenol suppressed TGF-β response by accelerating the turnover rate of TGF-β receptors.(In Vitro):Following 18hr exposure of murine BV-2 cells, at dose levels resulting in ≥80% viability (10 and 40 μM), limited alterations in pro-inflammatory responses were observed however, changes were observed in mitochondrial respiration. Basal respiration, ATP-linked respiration, maximum respiration, basal glycolytic and compensatory glycolysis were altered by Pentabromophenol. Phagocytosis was decreased for Pentabromophenol and TBBPA. NLRP3 inflammasome activation was assessed using BV-2-ASC (apoptosis-associated speck-like protein containing a CARD) reporter cells to visualize aggregate formation. Pentabromophenol, showed a direct stimulation of aggregate formation and properties as a NLRP3 inflammasome secondary trigger.

——

——

NSC 5717 | NSC-5717 | NSC5717

TGF-beta/Smad

TGFBR

GABA uptake

——

——

608-71-9

488.593

C6HBr5O

>98% (HPLC)

——

Oc1c(Br)c(Br)c(Br)c(Br)c1Br

——

(-20℃)

With Ice Pack

≥ 2 years